KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Assets (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Current Assets data on record, last reported at $240.2 million in Q4 2025.

  • For Q4 2025, Current Assets rose 77.77% year-over-year to $240.2 million; the TTM value through Dec 2025 reached $240.2 million, up 77.77%, while the annual FY2025 figure was $240.2 million, 77.77% up from the prior year.
  • Current Assets reached $240.2 million in Q4 2025 per RIGL's latest filing, up from $214.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $240.2 million in Q4 2025 and bottomed at $92.5 million in Q1 2024.
  • Average Current Assets over 5 years is $140.0 million, with a median of $127.8 million recorded in 2022.
  • Peak YoY movement for Current Assets: plummeted 35.45% in 2022, then skyrocketed 101.87% in 2025.
  • A 5-year view of Current Assets shows it stood at $154.5 million in 2021, then fell by 24.97% to $115.9 million in 2022, then dropped by 14.35% to $99.3 million in 2023, then soared by 36.1% to $135.1 million in 2024, then skyrocketed by 77.77% to $240.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $240.2 million in Q4 2025, $214.9 million in Q3 2025, and $175.4 million in Q2 2025.